Pulmonary embolism lastest guidelines

Reading File
Searching the Web

pulmonary embolism guidelines 2024 2025 ESC AHA latest recommendations

Searching PubMed

"pulmonary embolism"[MeSH Terms] AND "guideline"[pt]

Reading Web Page

https://www.ecccp.org/infographic-aha-acc-2026-guidelines-ac…

Reading Article

PMID: 41712677

Finding Sources
Reading File
Searching Images

pulmonary embolism risk stratification management algorithm CT angiography

A medical infographic and diagnostic algorithm in Portuguese for risk stratification of acute pulmonary embolism (APE). At the center is a diagnostic image: a transverse/axial CT pulmonary angiogram (CTPA) showing the mediastinum and major hilar vessels, including the pulmonary artery and heart chambers. The algorithm branches into three risk categories: 'Baixo Risco' (Low Risk), defined by a PESI score ≤ II and absence of right ventricular (RV) dilation; 'Alto Risco' (High Risk), characterized by circulatory shock (SBP < 90 mmHg) or cardiorespiratory arrest; and 'Risco intermediário' (Intermediate Risk). The intermediate section details an association of biomarkers across three scoring systems: the BOVA score (incorporating SBP, troponin, RV dysfunction, and heart rate), the TELOS score (lactate, troponin, and RV dysfunction), and the SHIELD score (shock index, lactate, hypoxemia, and RV dysfunction). Arrows indicate the clinical flow based on positive or negative scores, integrating clinical vitals, imaging findings of RV strain, and laboratory markers for triage and management.

A medical infographic and diagnostic algorithm in Portuguese for risk stratification of acute pulmonary embolism (APE). At the center is a diagnostic image: a transverse/axial CT pulmonary angiogram (CTPA) showing the mediastinum and major hilar vessels, including the pulmonary artery and heart chambers. The algorithm branches into three risk categories: 'Baixo Risco' (Low Risk), defined by a PESI score ≤ II and absence of right ventricular (RV) dilation; 'Alto Risco' (High Risk), characterized by circulatory shock (SBP < 90 mmHg) or cardiorespiratory arrest; and 'Risco intermediário' (Intermediate Risk). The intermediate section details an association of biomarkers across three scoring systems: the BOVA score (incorporating SBP, troponin, RV dysfunction, and heart rate), the TELOS score (lactate, troponin, and RV dysfunction), and the SHIELD score (shock index, lactate, hypoxemia, and RV dysfunction). Arrows indicate the clinical flow based on positive or negative scores, integrating clinical vitals, imaging findings of RV strain, and laboratory markers for triage and management.

This composite educational graphic combines diagnostic imaging and a clinical decision-making algorithm for the risk stratification of acute pulmonary embolism (PE). At the center is an axial view of a Contrast-Enhanced Computed Tomography (CT) scan of the chest, specifically a CT pulmonary angiogram (CTPA). The image displays the thoracic cage, lungs, mediastinum, and cardiac structures, notably demonstrating filling defects in the pulmonary arteries consistent with PE. The surrounding flowchart categorizes PE severity into three tiers: Low-Risk, Intermediate-Risk, and High-Risk. Low-Risk is defined by a Pulmonary Embolism Severity Index (PESI) score ≤ II and absence of Right Ventricular (RV) dilatation. High-Risk is identified by hemodynamic instability (circulatory shock, SBP < 90 mmHg, or cardiorespiratory arrest). The Intermediate-Risk section utilizes integrated biomarkers and scoring systems, including the BOVA score (focusing on SBP, troponin, RV dysfunction, and heart rate), the TELOS score (lactate, troponin, and RV dysfunction), and the SHIELD score (shock index, lactate, hypoxemia, and RV dysfunction). This educational visual illustrates how imaging findings of RV strain and clinical scores guide patient prognosis and triage.

This composite educational graphic combines diagnostic imaging and a clinical decision-making algorithm for the risk stratification of acute pulmonary embolism (PE). At the center is an axial view of a Contrast-Enhanced Computed Tomography (CT) scan of the chest, specifically a CT pulmonary angiogram (CTPA). The image displays the thoracic cage, lungs, mediastinum, and cardiac structures, notably demonstrating filling defects in the pulmonary arteries consistent with PE. The surrounding flowchart categorizes PE severity into three tiers: Low-Risk, Intermediate-Risk, and High-Risk. Low-Risk is defined by a Pulmonary Embolism Severity Index (PESI) score ≤ II and absence of Right Ventricular (RV) dilatation. High-Risk is identified by hemodynamic instability (circulatory shock, SBP < 90 mmHg, or cardiorespiratory arrest). The Intermediate-Risk section utilizes integrated biomarkers and scoring systems, including the BOVA score (focusing on SBP, troponin, RV dysfunction, and heart rate), the TELOS score (lactate, troponin, and RV dysfunction), and the SHIELD score (shock index, lactate, hypoxemia, and RV dysfunction). This educational visual illustrates how imaging findings of RV strain and clinical scores guide patient prognosis and triage.

This infographic presents misclassified examples from a multimodal classifier designed for Pulmonary Embolism (PE) risk stratification, comparing Electronic Health Record (EHR) features and 3D CT Pulmonary Angiography (CTPA) imaging. (a) Displays a false negative case featuring a bar chart of EHR feature importance (e.g., Pulmonary heart disease, Patients Complaint, CRP) and corresponding 3D Grad-CAM heatmaps overlaying the left ventricle and pulmonary artery. (b) Shows two false positive examples with their respective feature importance rankings (including Phosphorus, WBC, and Urea) and Grad-CAM visualizations. The heatmaps in these cases highlight the pulmonary trunk, aorta, right ventricle chamber, and areas indicating potential PE clots. This visual provides an educational comparison of how deep learning models utilize diverse data modalities to assess acute PE severity, illustrating anatomical regions of high diagnostic importance such as the heart chambers and major thoracic vessels. It serves as a study of model interpretability and the clinical relevance of multimodal diagnostic fusion.

This infographic presents misclassified examples from a multimodal classifier designed for Pulmonary Embolism (PE) risk stratification, comparing Electronic Health Record (EHR) features and 3D CT Pulmonary Angiography (CTPA) imaging. (a) Displays a false negative case featuring a bar chart of EHR feature importance (e.g., Pulmonary heart disease, Patients Complaint, CRP) and corresponding 3D Grad-CAM heatmaps overlaying the left ventricle and pulmonary artery. (b) Shows two false positive examples with their respective feature importance rankings (including Phosphorus, WBC, and Urea) and Grad-CAM visualizations. The heatmaps in these cases highlight the pulmonary trunk, aorta, right ventricle chamber, and areas indicating potential PE clots. This visual provides an educational comparison of how deep learning models utilize diverse data modalities to assess acute PE severity, illustrating anatomical regions of high diagnostic importance such as the heart chambers and major thoracic vessels. It serves as a study of model interpretability and the clinical relevance of multimodal diagnostic fusion.

I now have everything needed for a thorough, current answer. Here is the full summary:

Pulmonary Embolism: 2026 AHA/ACC Guidelines (Latest)

The most current and authoritative document is the 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults - published simultaneously in Circulation and JACC on February 19, 2026 (PMID: 41712677). This is the first-ever de novo dedicated PE guideline from the AHA/ACC - a landmark document replacing decades of extrapolated VTE guidance.

1. New 5-Tier Clinical Classification System (Categories A-E)

The biggest change is replacing the old Low/Intermediate/High-risk triad with a five-category physiological framework modeled on the SCAI cardiogenic shock staging:
CategoryDescriptionKey Features
AAt riskNo acute PE yet; risk factors present
BBeginning/MildHemodynamically stable, no RV strain, low severity score
CIntermediate (3 subcategories)C1: elevated severity score, normal RV + biomarkers; C2: RV dysfunction OR abnormal biomarkers; C3: both RV dysfunction AND elevated biomarkers
DDeterioratingNormotensive shock or rapid clinical deterioration; D1-D2 subcategories
EExtremis/High-riskOvert hemodynamic collapse, cardiac arrest; E1-E2 subcategories
New parameters incorporated: CPES score, National Early Warning Score 2 (NEWS2), serum lactate, and normotensive shock (preserved BP but impaired perfusion) - addressing a critical gap in prior classifications. Respiratory modifiers apply in C1-C3 when SpO2 < 90%, RR is high, or supplemental O2 is required.

2. Diagnosis

  • CTPA remains the primary imaging modality for confirmed PE diagnosis
  • V/Q scanning is preferred in pregnancy and for reducing radiation/contrast exposure
  • D-dimer: Use age-adjusted cutoffs (age x 10 mcg/L in patients >50 years); the pregnancy-adapted YEARS algorithm is referenced but with caution
  • Wells score / revised Geneva score remain valid pretest probability tools
  • Echocardiography: Key for RV assessment to drive C2/C3 vs D/E categorization
  • Troponin + BNP/NT-proBNP: Both are now formally incorporated into category assignment (BNP is new vs. ESC 2019, which emphasized only troponin)

3. Anticoagulation

  • DOACs are the preferred first-line anticoagulant (Class 1) for most patients without contraindications:
    • Rivaroxaban or apixaban (factor Xa inhibitors) - oral from the start, no parenteral bridge needed
    • Dabigatran or edoxaban - require 5-10 days of parenteral anticoagulation first
  • LMWH/UFH: Preferred in pregnancy, active cancer with GI involvement, and where DOACs are contraindicated
  • Duration: Minimum 3 months for provoked PE; longer or indefinite for unprovoked or recurrent VTE with high recurrence risk

4. Advanced (Reperfusion) Therapies - Updated Matrix

The guideline provides an Advanced Therapy Matrix mapping clinical category to specific intervention:
CategoryPreferred Advanced Therapy
A-C1Anticoagulation only (Class 3: do NOT use MT)
C2-C3Anticoagulation +/- consider catheter-directed therapy if deteriorating
D1-D2Catheter-directed thrombolysis (CDT) or mechanical thrombectomy (MT) - Class 2b for MT
E1Systemic thrombolysis OR MT - Class 2a for MT; surgical embolectomy if available
E2 (arrest)Systemic thrombolysis + ECMO; surgical embolectomy
Mechanical Thrombectomy (MT) - major update:
  • Class 2a recommendation for Category E1
  • Class 2b for selected D1-D2 patients (especially when bleeding risk is elevated)
  • Class 3 (not recommended) for low-risk (A-C1) - guardrail against overuse
  • Based partly on the PEERLESS RCT (2025) showing large-bore MT vs. CDT in intermediate-high risk PE
Systemic thrombolysis (e.g., alteplase 100 mg IV over 2h):
  • Reserved for Category E (hemodynamically unstable)
  • Contraindicated in low-to-intermediate risk; high bleeding risk (ICH ~2%)

5. Pulmonary Embolism Response Teams (PERTs) - Class 1

One of the most practice-changing recommendations: PERTs are now a formal Class 1 recommendation. These multidisciplinary teams (cardiology, pulmonology, EM, hematology, IR, CT surgery) provide rapid coordinated decisions for intermediate- and high-risk PE. This was not equivalent in the ESC 2019 document.

6. Outpatient Management

The guideline provides explicit criteria for early discharge and outpatient treatment (previously left to local protocols):
  • Category A/B patients with no significant comorbidity, reliable follow-up, and DOAC access can be discharged from the ED
  • The Hestia criteria and sPESI score guide safe discharge decisions

7. Anticoagulation Duration & Long-term Follow-up

  • 3 months minimum for all PE
  • Extended/indefinite therapy: Unprovoked PE with low-moderate bleeding risk, recurrent VTE, active cancer, antiphospholipid syndrome
  • Post-PE follow-up clinic at 3-6 months to assess for chronic thromboembolic pulmonary hypertension (CTEPH) - screen with echocardiography; confirm with V/Q scan and right heart catheterization if suspected
  • Aspirin is NOT recommended as a substitute for anticoagulation

8. Special Populations

  • Pregnancy: LMWH throughout; DOACs contraindicated; CTPA preferred over V/Q if needed; thrombolysis only for life-threatening PE
  • Cancer: LMWH or DOACs (edoxaban/rivaroxaban); caution with luminal GI malignancy due to bleeding risk
  • Renal impairment: UFH or dose-adjusted LMWH; avoid dabigatran if eGFR < 30
  • Right heart thrombus: Consider systemic thrombolysis or surgical removal; anticoagulation alone associated with high mortality

9. Key Differences vs. ESC 2019

FeatureESC 2019AHA/ACC 2026
Risk classificationLow/Intermediate-low/Intermediate-high/High5-tier A-E system
BNP in risk stratificationSupplementaryFormally incorporated
PERTsMentionedClass 1 recommendation
MT for intermediate-riskNot addressedClass 2b for D1-D2
Normotensive shockNot explicitly definedExplicitly categorized (D)
Outpatient managementLimited guidanceExplicit ED discharge criteria

PE Risk Stratification Algorithm

Key Supporting Trials (2025-2026)

  • PEERLESS RCT - Large-bore MT vs. CDT in intermediate-high risk PE (informs Class 2a/2b MT recommendations)
  • STORM-PE (2026) - MT with anticoagulation vs. anticoagulation alone
  • Hi-PEITHO, PEITHO-3, PEERLESS 2 - Ongoing/recently completed; will further refine intermediate-risk therapy
Note: The 2026 guideline has a published erratum (PMID: 42441758); verify the final published version for any corrected recommendations.
The ESC 2019 guidelines remain relevant for European practice and for topics not covered by the 2026 AHA/ACC document (DVT, VTE prevention/recurrence).
This is a shared conversation. Sign in to Orris to start your own chat.